Investigator Initiated Trial to Evaluate Cartilage Regeneration by Arthroscopy After JOINTSTEM Administration
NCT ID: NCT04821102
Last Updated: 2022-09-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
21 participants
INTERVENTIONAL
2023-07-01
2024-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Follow-up Study for Participants of Jointstem Investigator Initiated Trial by Arthroscopy
NCT04825730
Clinical Trial to Evaluate Efficacy and Safety of JOINTSTEM in Patients With Degenerative Arthritis
NCT02658344
A Phase 3 Study to Evaluate the Efficacy and Safety of JointStem in Treatment of Osteoarthritis
NCT03990805
A Phase 2b/3a Study to Evaluate the Efficacy and Safety of JointStem in Patients Diagnosed as Knee Osteoarthritis
NCT04368806
Follow-up Study for Participants of Jointstem Phase 3 Clinical Trial
NCT04427930
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
It primarily aims to regenerate cartilage. The intra-articular injection of JOINTSTEM is expected to stimulate the regeneration of cartilage, and to innovatively improve joint function with cartilage regeneration.
The subjects of this therapy were patients with K\&L grade 3 aged 20 or older.
This study is a double-blind, randomized, placebo controlled study with two arms to evaluate JOINTSTEM as a treatment for subjects with osteoarthritis. Following a 2-week screening period, approximately 21 patients will be randomly assigned into one of the following two arms in a 2:1 ratio (2 JointStem : 1 placebo control). After each patient completes 12-month visit (Visit 6) and the data management team confirms all data have no issue, the individual database will be locked and the blinding will be open for the statistical analysis.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
JOINTSTEM
Autologous Adipose Tissue derived MSCs
JOINTSTEM
JOINTSTEM Autologous Adipose Tissue derived MSCs 1x10\^8cells/(saline), 1 time injection under ultrasonic guided
Saline
saline
Saline
saline, 1 time injection under ultrasonic guided
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
JOINTSTEM
JOINTSTEM Autologous Adipose Tissue derived MSCs 1x10\^8cells/(saline), 1 time injection under ultrasonic guided
Saline
saline, 1 time injection under ultrasonic guided
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Patients must consent in writing to participate in the study by signing and dating an informed consent document
3. Diagnosis of degenerative arthritis of class 1-3 by ACR(American College of Rheumatology Criteria) Global functional criteria
4. Diagnosis of Kellgren and Lawrence grade 3 by radiographic criteria
5. Patients suitable for one of three conditions of 'diagnostic criteria for osteoarthritis of knee' based on ACR guideline
* clinical and inspectional opinion
* clinical and radiographic opinion
* clinical opinion
6. Patients who has joint pain ≥ 50mm on 100mm VAS (Visual Analog Scale) at Screening
7. Patient who has WOMAC score ≥ 1000 at Screening
8. No improvement with persisting knee pain at least for 12 weeks (3 months) by nonoperational therapy before Screening
Exclusion Criteria
* Appropriate contraception method: Use of condom, contraceptive sponges, foam, diaphragm, intrauterine device etc.
* Periodic abstinence(e.g. methods of predicting ovulation) and moderation are not considered as appropriate contraception method.
* Not allowed to use hormonal contraceptives
* Childbearing age female patients, exclude menopausal female (amenorrhea for more than 24 months after the last menstruation) or female who has no possibility of pregnency by surgical sterilization operation, can participate in this study only determined negative in pregnancy test
2. Pregnant women or lactating mothers
3. Patients with Body Mass Index (BMI) \> 35
4. Patients with positive human immunodeficiency (HIV), hepatitis B (HBV), hepatitis C (HCV), syphilis at screening indicative of current of pass infection
5. Patients with other disease including
* Septic arthritis, Rheumatoid or Inflammatory joint disease, Gout, Reccurent pseudogout, Paget disease, Articular fractures, Ochronosis, Acromegaly, Hemochromatosis, Wilson's disease,Osteochondromatosis, Hereditary disorder, Genetic disorder of collagen
6. Patients who are diagnosed with malignant tumor in the past or present
7. Patients who have clinically significant diseases including
* Cardiac disorder (Myocardial infarction, Coronary artery bypass graft, Arrhythmia and other severe Cardiac disorder etc.)
* Resistant hypertension (systolic blood pressure \> 160mmHg or diastolic pressure \> 100mmHg at Screening)
* Kidney disease (Chronic renal failure, Glomerulonephritis etc.)
* Liver disease (Hepatocirrhosis, Fatty liver, acute or chronic liver disease etc.)
* Endocrinopathy (Thyroiditis, Diabetes insipidus, Cushing disease etc.)
8. Patients who have significant lab abnormalities
9. Patients who have severe pain in other areas that can affect the judgement of knee joint symptom
10. Patients who underwent any arthroscopic surgery on the injection site within 6 months of the screening visit date, or scheduled to perform any surgery during the clinical trial period
11. Patients who received any drug by intra-articular injection(hyaluronic acid or steroid etc.) for treatment within 6 months prior to Screening
12. Patients who experienced as stem cell therapy or blood product injection(PRP, Prolo therapy etc.)
13. Patients who received treatment within 14 days prior to Screening including(But, patients who had wash-out-period can participate in this study)
* Take medicines including composition of Glucosamine, Chondretin sulphate and Diacerhein etc.
* Take phytotherapeutic agent or Chinese medicine for osteoarthritis
* Take antiinflammatory analgesic drug, NSAIDs (prescription/nonprescription pharmaceuticals) etc. (Patients who have 3 days of wash-out-period after they took acetaminophen can participate in the study)
* Take oral steroids
14. Patients with penicillin hypersensitivity reactions
15. Patients with skin diseases or infections in the area of the injection site
16. Patients who have abnormal flail over grade 2 flail knee test of anterior to posterior and varus/valgus lesion at physical examination
17. Patients who have difficulty in taking MRI because of metal materials (cardiac pacemaker or clip of cerebral artery etc.) in their body or claustrophobia -but, patients with metal materials that are not affected by magnetic field can participate in this study
18. Patients who have difficulty in liposuction or local anesthesia
19. Patients who have alcohol, drug abuse history
20. Patients who have severe neurologic and psychiatric disorders that affect clinical trials
21. Patients who had participated in other clinical trials within 12 weeks prior to this study
22. Patients who the principal investigator considers inappropriate for the clinical trial due to any other reasons than those listed above
20 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
R-Bio
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
CHANGMIN LEE, M.D.,Ph.D.
Role: PRINCIPAL_INVESTIGATOR
Bethesda Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Bethesda Hospital
Yangsan, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BS-JS-IIT1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.